Cover Image

Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients-A Systematic Review and Meta-Analysis

Background/Objectives: The study aimed to evaluate the efficacy and safety of incorporating bevacizumab into the combination therapy of carboplatin and paclitaxel for epithelial ovarian cancer and other clinical applications. Methods: A systematic review was conducted following PRISMA guidelines usi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yu Jin Kim (Author), Hee Min Lee (Author), Ga Eun Lee (Author), Jin Hui Yoo (Author), Hwa Jeong Lee (Author), Sandy Jeong Rhie (Author)
Format:	Book
Published:	MDPI AG, 2024-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer
by: Masafumi Yasunaga, et al.
Published: (2022)

Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis
by: Wanjun Tao, et al.
Published: (2020)

Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
by: Madison R. Klavans, et al.
Published: (2020)

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients
by: Zhenhua Du, et al.
Published: (2015)

Effects of Piperazine Derivative on Paclitaxel Pharmacokinetics
by: Jaeok Lee, et al.
Published: (2019)

Squamous cell carcinoma arising from a mature cystic teratoma of the ovary: Successful treatment with carboplatin, paclitaxel, and bevacizumab
by: Mika Fukase, et al.
Published: (2020)

Analysis of the toxicity induced by carboplatin and paclitaxel regimen in ovarian cancer patients
by: Thaís A. GOUVÊA, et al.
Published: (2022)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
by: Sally Mullany, et al.
Published: (2020)

Pharmacokinetic Alteration of Paclitaxel by Ferulic Acid Derivative
by: Jaeok Lee, et al.
Published: (2019)

Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer
by: Wei-Chun Chen, et al.
Published: (2020)

Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen
by: Szu-Ting Yang, et al.
Published: (2024)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
by: Huan Wang, et al.
Published: (2022)

Survival and Side Effects of Cisplatin/Cyclophosphamide and Carboplatin/Paclitaxel Adjuvant Chemotherapy in Stage IC-IV Ovarian Cancer
by: Unedo H Markus, et al.
Published: (2015)

Lethal Clostridium difficile Colitis Associated with Paclitaxel and Carboplatin Chemotherapy in Ovarian Carcinoma: Case Report and Review of the Literature
by: V. Masciullo, et al.
Published: (2010)

A case of metastatic basal cell carcinoma treated with carboplatin and paclitaxel
by: Chryssoula Papageorgiou, et al.
Published: (2023)

Durable remission in a patient with ERBB2-amplified recurrent mucinous ovarian carcinoma treated with Trastuzumab-Carboplatin-Paclitaxel
by: Alexander J. Neil, et al.
Published: (2023)

Comparison of Antiemetic Effects of Ondansetron Granisetron and Tropisetron For Acute Emesis In Ovarian Cancer Patients Receiving Chemotherapy With Paclitaxel and Carboplatin
by: Taner Turan, et al.
Published: (2007)

GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel‐Based Chemotherapy in Ovarian Cancer
by: Amanda Canato Ferracini, et al.
Published: (2021)

Synergistic Encapsulation of Paclitaxel and Sorafenib by Methoxy Poly(Ethylene Glycol)-<i>b</i>-Poly(Caprolactone) Polymeric Micelles for Ovarian Cancer Therapy
by: Chae Eun Jin, et al.
Published: (2023)

Inflammation of Actinic Keratoses Induced by Combination of Carboplatin and Paclitaxel: Two Case Reports
by: Špela Šuler Baglama, et al.
Published: (2022)

Quantification of Teicoplanin Using the HPLC-UV Method for Clinical Applications in Critically Ill Patients in Korea
by: Jaeok Lee, et al.
Published: (2021)

Responses and adverse effects of carboplatin-based chemotherapy for pediatric intracranial germ cell tumors
by: Suntae Ji, et al.
Published: (2011)

The Serum Level of Vascular Endothelial Growth Factor (VEGF) is Declined after Paclitaxel-Carboplatin Combined Chemotherapy Treatment on Epithelial Ovarian Cancer
by: Amelia Abdullah
Published: (2012)

The Serum Level of Vascular Endothelial Growth Factor (VEGF) is Declined after Paclitaxel-Carboplatin Combined Chemotherapy Treatment on Epithelial Ovarian Cancer
by: Amelia Abdullah
Published: (2012)

Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
by: Yingkai Chen, et al.
Published: (2022)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
by: Sevgi Ayhan, et al.
Published: (2023)

Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis
by: Wenjian Gong, et al.
Published: (2023)

Stage III malignant mixed Müllerian tumor of the fallopian tube: A case of 5-year survival after optimal debulking and adjuvant chemotherapy with paclitaxel plus carboplatin
by: Ching-Pei Tsai, et al.
Published: (2012)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
by: Maurie Markman
Published: (2009)

Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland
by: Xiaoting Liu, et al.
Published: (2024)

Design and Characterization of Carboplatin and Paclitaxel Loaded PCL Filaments for 3D Printed Controlled Release Intrauterine Implants
by: Cem Varan, et al.
Published: (2023)

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience
by: Maria Rubinstein, et al.
Published: (2019)

Synthetic Triterpenoids Can Protect against Toxicity without Reducing the Efficacy of Treatment with Carboplatin and Paclitaxel in Experimental Lung Cancer
by: Karen T. Liby
Published: (2014)

Critical appraisal of bevacizumab in the treatment of ovarian cancer
by: Yoshida H, et al.
Published: (2015)

Recurrent Pseudomembranous Colitis in an Ovarian Cancer Patient Undergoing Carboplatin Chemotherapy
by: Valerie A. Allen, et al.
Published: (2016)

Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin
by: Jing Zhang, et al.
Published: (2021)

Paclitaxel-related nail toxicity
by: Szu-Ting Yang, et al.
Published: (2019)

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
by: Jeayeon Park, et al.
Published: (2024)

LncRNA RBAT1 reduces chemosensitivity of cancer cells to carboplatin/paclitaxel by sponging miR‑27b in endometrial carcinoma
by: Lingye Fan, et al.
Published: (2023)

Complete response in hepatocellular carcinoma with lymph node metastasis by combination therapy of atezolizumab and bevacizumab: a case report
by: Sang Youn Hwang, et al.
Published: (2021)